DIA: Driving Insights to Action
Science:Life Sciences
FDA has approved 11 biosimilars, but 41 biosimilars have been approved for use in Europe. The DIA 2018 Global Annual Meeting session “Interchangeable Biosimilars: A Global Perspective” explored the circumstances behind this difference and ways and reasons to close this gap, led by Session Chair Nielsen Hobbs (Executive Editor, US Policy & Regulatory, The Pink Sheet/Scrip), who was interviewed by DIA Senior Digital Copy Editor Chris Slawecki for this podcast. Watch the video of this podcast interview.
Patient-Focused Drug Development: What Must We Still Do?
Game Technology Opens New Path to Clinical Endpoints
Challenges and Opportunities for South Africa’s New Regulatory System
Clinical, Data, and Quantitative Science Now Converging
Realizing the Full Potential of CRISPR: Is the Hype Getting in the Way of Progress?
Tackling Ethical Questions in Clinical Research and Drug Development
WHO 2030 Framework for Efficient, Effective Regulation
AI: Opportunity for More Informed Drug Development Decisions
Clinical Training Critical in China’s Cancer Fight
Changing Research in China: From Generics to Innovators
Running Away from Addiction Has Caught Up with US
Has the Time for Big/Real World Data Finally Arrived?
Will AI Make Workers More (or Less) Valuable?
PvPI: Technology Meets Opportunity to Improve Safety
New EU CTR: One Application, One Portal, One Decision
US Generic Drug Policy: Less Cost, Same Impact
Multiple Pathways Complicate Opioid Pain Management
Breakthrough for Patients & Regulatory Science
DIA 2018 Co-Chair: Patient Activists Are “Our Best Friends”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology